网站标志
导航菜单
购物车
购物车 0 件商品 | 查看购物车 | 我的订单 | 我的积分 | 会员中心
当前日期时间
当前时间:
商品搜索
商品搜索:
价格
点评详情
点评详情
发布于:2018-5-7 16:08:42  访问:3 次 回复:0 篇
版主管理 | 推荐 | 删除 | 删除并扣分
Dabrafenib Info In Addition To The Ill Informed Beliefs
The overall cumulative proportion of patients achieving HBV DNA levels <400 copies/ml (<60?IU/ml) was 79% after a mean 23?months of treatment. Although LMV resistance did not influence the antiviral efficacy of TFV, the presence of ADV resistance impaired TFV efficacy. However, virological breakthrough was not observed in any of the patients during the entire observation period [29]. It is important to note that different results have been obtained in a clinical trial comparing different treatments in patients with CHB who had an incomplete response to ADV. A combination of fixed-dose FTC and TFV from the start (early combination) vs TFV as monotherapy was evaluated. ZVADFMK Viral decay curves were identical in the groups through week 24 ERK inhibitor (direct comparison of blinded therapy). At week 48, 81% of patients initially given TFV or TFV+FTC (Truvada) had undetectable HBV DNA levels. The presence of baseline LMV- or ADV-associated mutations did not affect the virological response. Adherence to therapy appeared to be the primary factor associated with achieving undetectable HBV DNA levels at week 48 [30]. In contrast, a recent Australian study analysed the efficacy of TFV in mainly Asian patients with CHB who had previously failed LMV and had significant viral replication despite at least 24?weeks of treatment with ADV. At 48 and 96?weeks, 46 and 64% patients achieved undetectable HBV DNA. The response was independent of baseline LMV therapy or mutations conferring ADV resistance. The presence of ADV resistance substitutions (rtA181T vs rtN236T?��?rtA181T/V) at baseline affected the subsequent virologic response to the TFV switch, compared with na?ve patients [28], with significant levels of persistent viremia especially if the double mutation rtA181T/V+rtN236T was present at baseline Dabrafenib order (Table?1). The antiviral efficacy of the combination of TFV+FTC (Truvada) for treatment intensification in patients who failed different lines of NA therapies as shown by persistently detectable viremia is very good. Kaplan�CMeier analysis has shown that after treatment intensification with this combination, the probability achieving undetectable HBV DNA was 76% by week 48, and 94% by week 96. No viral breakthrough occurred [67]. It is important to note that the combination of TFV plus LMV has not shown to be beneficial compared with TFV alone in most studies [28]. European studies of ETV in clinical practice have shown that this drug is as effective in achieving viral suppression in na?ve patients as in LMV or ADV exposed patients, as long as LMV resistance (detectable rtM204V/I) does not develop [68]; not surprisingly, the presence of ADV resistance did not adversely influence the effect of ETV in this cohort [68].
共0篇回复 每页10篇 页次:1/1
共0篇回复 每页10篇 页次:1/1
我要回复
回复内容
验 证 码
看不清?更换一张
匿名发表 
脚注信息
Copyright (C) 2015-2016 All Rights Reserved. 光明云南石斛商城管理系统 版权所有   滇ICP备11005439号-1
服务时间:周一至周日 09:00 — 18:00  全国订购及服务热线:0691-5161027 
联系地址:云南省西双版纳傣族自治州勐海县工业园区   邮政编码:666200